Associations between high density lipoprotein mean particle size and serum paraoxonase--1 activity

Journal of Research in Medical Sciences

Volumn 17, Issue 11, 2012, Pages 1020-1026

  Razavi, Amirnader Emami ^a   Ani, Mohsen ^a   Pourfarzam, Morteza ^a   Naderi, Gholam Ali ^b  

^a Novel Drug Delivery Systems Research Centre   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dynamic light scattering; HDL C; High density lipoprotein size; Paraoxonase 1 activity; Zetasizer

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CHEMICAL ANALYSIS; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; HUMAN; LIGHT SCATTERING; MALE; NORMAL HUMAN; PARTICLE SIZE; PATHOGENESIS; PROGNOSIS; ULTRAVIOLET SPECTROPHOTOMETRY; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 84874684245     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Cooney M, Dudina A, De Bacquer D, Wilhelmsen L, Sans S, Menotti A, et al. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis 2009;206:611-6.
2. Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 2000;86:11L-14L.
3. Toth PP. Reverse cholesterol transport: High-density lipoprotein's magnificent mile. Curr Atheroscler Rep 2003;5:386-93.
4. Cheung MC, Segrest JP, Albers JJ, Cone JT, Brouillette CG, Chung BH, et al. Characterization of high density lipoprotein subspecies: Structural studies by single vertical spin ultracentrifugation and immunoaffinity chromatography. J Lipid Res 1987;28:913-29.
5. Perusse M, Pascot A, Despres JP, Couillard C, Lamarche B. A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma. J Lipid Res 2001;42:1331-4.
6. Cho KH, Park SH, Park JE, Kim YO, Choi I, Kim JJ, et al. The function, composition, and particle size of high-density lipoprotein were severely impaired in an oliguric phase of hemorrhagic fever with renal syndrome patients. Clin Biochem 2008;41:56-64.
7. Kwiterovich PO Jr. Lipoprotein heterogeneity: Diagnostic and therapeutic implications. Am J Cardiol 2002;90:1i-10i.
8. Murphy A, Chin-Dusting J, Sviridov D, Woollard K. The anti inflammatory effects of high density lipoproteins. Curr Med Chem 2009;16:667-75.
9. Efrat M, Aviram M. Paraoxonase 1 Interactions with HDL, Antioxidants and Macrophages Regulate Atherogenesis A Protective Role for HDL Phospholipids. Adv Exp Med Biol 2010:153-66.
10. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004;318:680-683.
11. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 2002;277:4301-8.
12. James RW, Deakin SP. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004;37:1986-94.
13. Wang M, Lang X, Cui S, Zou L, Cao J, Wang S, et al. Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk. DNA Cell Biol 2012;31:975-82.
14. Fathy MM, Youssif OA, Ashour WM. The slow activity-associated genotype of microsomal epoxide hydroxylase-1 (m-EPHX-1) and low serum paraoxonase-1 (PON1) activity are associated with increased susceptibility to chronic obstructive pulmonary disease (COPD) in smokers. Comparative Clinical Pathology 2012:1-7.
15. Lakshman R, Garige M, Gong M, Leckey L, Varatharajalu R, Zakhari S. Is alcohol beneficial or harmful for cardioprotection? Genes Nutr 2010;5:111-120.
16. van Himbergen TM, Roest M, de Graaf J, Jansen EH, Hattori H, Kastelein JJ, et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 2005;46:445-51.
17. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003;23:1881-8.
18. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003;107:2775-9.
19. Troughton JA, Woodside JV, Yarnell JW, Arveiler D, Amouyel P, Ferrières J, et al. Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: The PRIME study. Atherosclerosis 2008;197:556-63.
20. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451-7.
21. van Himbergen TM, van der Schouw YT, Voorbij HA, van Tits LJ, Stalenhoef AF, Peeters PH, et al. Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis 2008;199:408-14.
22. Mehta RH, Califf RM, Garg J, White HD, Van de Werf F, Armstrong PW, et al. The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction. Eur Heart J 2007;28:415-24.
23. Beltowski J, Wojcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: The possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003;170:21-9.
24. Bronzert TJ, Brewer HB Jr. New micromethod for measuring cholesterol in plasma lipoprotein fractions. Clin Chem 1977;23:2089-98.
25. Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978;87:206-210.
26. Rawle A. PCS in 30 minutes. Malvern, UK: Malvern Instruments Inc; 1995.
27. Gharipour M, Baghaie AM, Boshtam M, Rabeie K. Prevalence of metabolic syndrome in An Iranian Adult population. ARYA Atherosclerosis 2010;1.
28. Jayakumari N, Thejaseebai G. High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease. J Clin Biochem Nutr 2009;45:278-84.
29. Rosenblat M, Aviram M. Paraoxonases role in the prevention of cardiovascular diseases. Biofactors 2009;35:98-104.
30. Hasselwander O, McEneny J, McMaster D, Fogarty DG, Nicholls DP, Maxwell AP, et al. HDL composition and HDL antioxidant capacity in patients on regular haemodialysis. Atherosclerosis 1999;143:125-33.
31. Chen X, Wu Y, Liu L, Su Y, Peng Y, Jiang L, et al. Relationship between high density lipoprotein antioxidant activity and carotid arterial intima-media thickness in patients with essential hypertension. Clin Exp Hypertens 2010;32:13-20.
32. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomic of the paraoxonase (PON1) polymorphisms: Effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003;54:371-92.
33. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000;20:2441-7.
34. Leviev I, Righetti A, James RW. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med (Berl) 2001;79:457-63.
35. Saha N, Roy AC, Teo SH, Tay JS, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991;40:277-82.
36. Mackness MI, Peuchant E, Dumon MF, Walker CH, Clerc M. Absence of "A"-esterase activity in the serum of a patient with Tangier disease. Clin Biochem 1989;22:475-8.
37. Mackness MI, Walker CH, Carlson LA. Low A-esterase activity in serum of patients with fish-eye disease. Clin Chem 1987;33:587-8.
38. James RW, Blatter Garin MC, Calabresi L, Miccoli R, von Eckardstein A, Tilly-Kiesi M, et al. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis 1998;139:77-82.
39. Blatter Garin MC, Moren X, James RW. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res 2006;47:515-20.
40. Rojas-Garcia A, Solis-Heredia M, Pina-Guzman B, Vega L, Lopez-Carrillo L, Quintanilla-Vega B. Genetic polymorphisms and activity of PON1 in a Mexican population. Toxicol Appl Pharmacol 2005;205:282-9.
41. Pascot A, Lemieux I, Prud'homme D, Tremblay A, Nadeau A, Couillard C, et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001;42:2007-14.
42. Watanabe H, Soderlund S, Soro-Paavonen A, Hiukka A, Leinonen E, Alagona C, et al. Decreased high-density lipoprotein (HDL) particle size, prebeta, and large HDL subspecies concentration in Finnish low-HDL families: Relationship with intima-media thickness. Arterioscler Thromb Vasc Biol 2006;26:897-902.
43. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996;247:71-80.
44. Schiavon R, Battaglia P, De Fanti E, Fasolin A, Biasioli S, Targa L, et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: Comparison with the PON1 allele polymorphism. Clin Chim Acta 2002;324:39-44.
45. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998;18:1046-53.
46. Sakuma N, Yoshikawa M, Hibino T, Ohte N, Kamiya T, Kunimatsu M, et al. HDL3 exerts a more powerful antiperoxidative and protective effect against peroxidative modification of LDL than HDL2 does. J Nutr Sci Vitaminol (Tokyo) 2002;48:278-82.
47. Yoshikawa M, Sakuma N, Hibino T, Sato T, Fujinami T. HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. Clin Biochem 1997;30:221-5.